IVERIC bio, Inc. Common Stock
ISEE
ISEE was delisted on the 10th of July, 2023.
184 hedge funds and large institutions have $1.11B invested in IVERIC bio, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 61 increasing their positions, 54 reducing their positions, and 18 closing their positions.
128% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 18
118% more call options, than puts
Call options by funds: $33M | Put options by funds: $15.1M
13% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 54
13% more funds holding
Funds holding: 163 → 184 (+21)
42% less funds holding in top 10
Funds holding in top 10: 12 → 7 (-5)
44% less capital invested
Capital invested by funds: $1.99B → $1.11B (-$874M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$84.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$35.7M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$33.7M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$29.1M |
| 5 |
O
OrbiMed
New York
|
+$17.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$75.9M |
| 2 |
PA
Perceptive Advisors
New York
|
-$39.4M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$30.3M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$28.3M |
| 5 |
Jennison Associates
New York
|
-$24M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
C
201
Covestor
London,
United Kingdom
| – | -$75 | -6 | -25% |
|
|
AF
202
Allworth Financial
Folsom,
California
| – | +$151 | +12 | New |
|
203
Osaic Holdings
Scottsdale,
Arizona
| – | +$176 | +14 | New |
|
ISEE Hedge Fund Activity: Q2 2022 in Review
184 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q2 2022, worth a combined $1.11B — down 44% from $1.99B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new ISEE positions and 18 closed out — a net gain of 23 holders — while 61 added to existing stakes and 54 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $84.2M. The largest seller was Avidity Partners Management, cutting an estimated $75.9M.
- 184 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q2 2022, up from 163 in Q1 2022.
- Funds reported $1.11B of IVERIC bio, Inc. Common Stock stock for Q2 2022, down 44% quarter-over-quarter.
- 41 funds opened new IVERIC bio, Inc. Common Stock positions in Q2 2022 and 18 closed out, a net change of +23 holders.
- The largest IVERIC bio, Inc. Common Stock buyer in Q2 2022 was Janus Henderson Group, an estimated $84.2M added.
- The largest IVERIC bio, Inc. Common Stock seller in Q2 2022 was Avidity Partners Management, an estimated $75.9M sold.
Based on aggregated 13F filings for Q2 2022.